Cryo-Cell International Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: |
|
, |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On October 29, 2024 the Board of Directors of Cryo-Cell International, Inc. ("Cryo-Cell") declared a cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024 and is expected to be paid on November 29, 2024.
.
Item 9.01 Financial Statements and Exhibits.
.
|
Financial Statements of Businesses Acquired. |
Not Applicable. |
|
Pro Forma Financial Information |
Not Applicable. |
|
Shell Company Transactions |
Not Applicable. |
|
Exhibits. |
|
|
Exhibit No. |
Description |
|
99.1 |
|
|
104 |
Cover Page Interactive Data File (the cover page iXBRL tags are embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Cryo-Cell International, Inc. |
|
|
|
|
Date: |
October 30, 2024 |
By: |
/s/ David Portnoy |
|
|
|
David Portnoy, Chairman and Co-CEO |